|
|
|
|
|
Indications for use
|
Severe endometriosis
|
- to reduce vascularity or reduce symptoms prior to surgery
|
|
Fibroids (>3cm diameter on ultrasound)
|
- to induce shrinkage prior to surgery
|
|
Chronic pelvic pain
|
- as a test to assess likely success of hysterectomy / oophorectomy
|
|
Ovarian entrapment
|
- as a test to assess likely success of oophorectomy
|
|
Dysfunctional uterine bleeding (DUB)
|
- endometrial preparation prior to endometrial ablation
|
|
To protect ovarian function
|
- prior to radiotherapy / chemotherapy
|
|
Maximum length of treatment
|
| | | | | | | | Dysfunctional uterine bleeding
|
| | To protect ovarian function
|
| |
|
|
Treatment
|
Nafarelin nasal spray 200 micrograms, TWICE per day.
|
or
|
Goserelin depot injection 3.6mg, per month (if unable to tolerate nasal spray).
|
Procedure
|
All scripts for Gonadotrophin Releasing Hormone (GnRH) must:
|
- be signed by the appropriate head of unit; and
|
- have the indication for use
|
|
Royal Women's Hospital Clinical Practice Guidelines (CPGs) are intended to provide guidance to health care professionals, based on a thorough evaluation of research evidence, on the practical assessment and management of specific clinical issues or situations. The guidelines allow some flexibility on the part of the health care professional based on the needs of the specific patient for whom they are caring.
|
Please remember to read our disclaimer.
|
